Results 201 to 210 of about 922,079 (252)
"Eugenics is an integral aspect of our global scientific and political culture:" interview with Marius Turda. [PDF]
Turda M, Mannheimer V.
europepmc +1 more source
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Revisit intentions of sports tourists: an extended theory of planned behavior approach. [PDF]
Gao W, Cao D, Lyu T, Yang Y.
europepmc +1 more source
Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla +10 more
wiley +1 more source
Expanding recruitment to medical school: the motivations for and perceived barriers to entry of non-science entrants to a graduate-entry medical course: a qualitative study. [PDF]
Sinyor J, Muscroft L.
europepmc +1 more source
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff +11 more
wiley +1 more source
Leaving Academia: Dual-Career Relationships and Partners' Attrition from Academic Careers. [PDF]
Fisher JA, Tao Y, Waltz M, Monahan T.
europepmc +1 more source
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
In love with medical humanities! A survey on medical students' opinions and satisfaction with an integrated elective course. [PDF]
Tusoni F +8 more
europepmc +1 more source

